Search Results - "Niclou, S.P"

161 INVITED Stem Cells by Niclou, S.P, Golebiewska, A, Stiebe, D, Bjerkvig, R

Get full text

277 Identification of Novel Therapeutic Targets Through an Integrated in Vitro and in Vivo Whole Genome ShRNA Screen in Glioma Stem Cells by Sanzey, M, Golebiewska, A, Stieber, D, Nazarov, P, Muller, A, Vallar, L, Niclou, S.P

Get full text

641 Endogenous Inhibitors of Tyrosine Kinase Receptors –a Therapeutic Role for Soluble LRIG1 in Malignant Glioma? by Tiemann, K, Bernard, A, Fack, F, Johansson, M, Hedman, H, Niclou, S.P

Get full text

249 Side Population in Human Glioblastoma Does Not Characterize Cancer Stem Cell Populations and is Exclusively Stroma-derived by Golebiewska, A, Bougnaud, S, Stieber, D, Brons, N.H.C, Vallar, L, Hertel, F, Bjerkvig, R, Niclou, S.P

Get full text

New hints towards a precision medicine strategy for IDH wild-type glioblastoma by White, K., Connor, K., Clerkin, J., Murphy, B.M., Salvucci, M., O'Farrell, A.C., Rehm, M., O'Brien, D., Prehn, J.H.M., Niclou, S.P., Lamfers, M.L.M., Verreault, M., Idbaih, A., Verhaak, R., Golebiewska, A., Byrne, A.T.

“…Glioblastoma represents the most common primary malignancy of the central nervous system in adults and remains a largely incurable disease. The elucidation of…”
Get full text

P17.29IDENTIFICATION OF NOVEL MOLECULAR TARGETS FOR TEMOZOLOMIDE-BASED THERAPIES AGAINST GLIOBLASTOMA: A COMPREHENSIVE SHRNA-BASED SCREEN OF DNA REPAIR FACTORS by Erasimus, H., Fritah, S., Haan, S., Niclou, S.P., Van Dyck, E.

“…Glioblastoma multiforme (GBM) is an aggressive brain tumor with poor prognosis (the median survival of GBM patients is 14.6 months). Current GBM treatment,…”
Get full text

O1.05AXITINIB, A SELECTIVE VEGFR-1,-2,-3 TYROSINE KINASE INHIBITOR, INHIBITS TUMOR GROWTH AND INCREASES INFILTRATION OF IMMUNE CELLS IN AN INTRACRANIAL MELANOMA MOUSE MODEL by Du Four, S., Maenhout, S.K., Niclou, S.P., Thielemans, K., Neyns, B., Aerts, J.L.

“…VEGF is a key mediator of pathological cancer associated neoangiogenesis and immunosuppression. VEGFR targeted therapy holds promise to counteract cancer…”
Get full text

PO-014 Dianhydrogalactitol (vaL-083) reduces glioblastoma tumour progression in vivo, upon bevacizumab-induced hypoxia by Golebiewska, A., Oudin, A., Steino, A., Bacha, J.A., Brown, D.M., Niclou, S.P.

“…Standard-of-care for glioblastoma (GBM) includes surgery, radiation and temozolomide. Nearly all tumours recur and 5 year survival is less than 3%, largely due…”
Get full text

O4.09IN SITU METABOLIC PROFILING SHEDS LIGHT ON OXIDATIVE STRESS PATHWAYS IN IDH1 MUTANT OLIGODENDROGLIOMA by Fack, F., Hochart, G., Oudin, A., Keunen, O., Leenders, W.P., Gottlieb, E., Bjerkvig, R., Stauber, J., Niclou, S.P.

“…BACKGROUND: The oncometabolite D-2-hydroxyglutarate (2-HG) is strongly increased in glial tumors presenting a heterozygous point mutation in isocitrate…”
Get full text

P16.24MULTIMODAL IMAGING ELUCIDATES PHYSIOLOGICAL AND METABOLIC CHANGES INDUCED BY ANTI-ANGIOGENIC THERAPY IN GLIOBLASTOMA by Keunen, O., Obad, N., Espedal, H., Jiřík, R., Rygh, C.Brekke, Taxt, T., Sakariassen, P., Fack, F., Niclou, S.P., Bjerkvig, R.

“…Treatment of primary and recurrent glioblastoma with anti-angiogenic therapies, either alone or in combination with chemotherapy, fails to extend overall…”
Get full text

PO-197 Patient-derived xenograft (PDX) models of glioblastoma: from basic research to preclinical studies by Golebiewska, A, Hau, AC, Stieber, D, Oudin, A, Azuaje, F, Tony, K, Poovathingal, S, Skupin, A, Bjerkvig, R, Niclou, SP

“…IntroductionAnimal models are essential tools for basic research and preclinical therapeutic interventions. Although numerous clinical cancer trials are being…”
Get full text

SPOT-006 Stem cell-associated heterogeneity in glioblastoma is a result of intrinsic tumour plasticity shaped by the microenvironment by Golebiewska, A, Dirkse, A, Buder, T, Poovathingal, S, Muller, A, Herold-Mende, C, Bjerkvig, R, Deutsch, A, Voss-Böhme, A, Niclou, SP

“…IntroductionTo date there is no curative treatment available for patients with Glioblastoma (GBM). The cancer stem cell (CSC) hypothesis posits that GBMs rely…”
Get full text